Press Release
<< Back
Verastem Issued U.S. Patent Covering VS-4718 Composition of Matter
Preclinical models of multiple tumor types have established the FAK
pathway as critical for the growth and survival of cancer stem cells,
which are an underlying cause of tumor metastasis and recurrence.
“This patent is the cornerstone of our intellectual property estate for
VS-4718, a potent inhibitor of FAK which we believe holds significant
potential in the treatment of a variety of cancers,” said
About Verastem, Inc.
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, including
defactinib and VS-4718, and the Company’s FAK and diagnostic programs
generally, the timeline for clinical development and regulatory approval
of the Company’s compounds, the structure of the Company’s planned
clinical trials and estimates of the Company’s ability to fund
operations. The words “anticipate,” “appear,” “believe,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying
words. Each forward-looking statement is subject to risks and
uncertainties that could cause actual results to differ materially from
those expressed or implied in such statement. Applicable risks and
uncertainties include the risks that the preclinical testing of the
Company’s compounds and preliminary data from clinical trials may not be
predictive of the results or success of later clinical trials, that the
Company will be unable to successfully complete the clinical development
of its compounds, including defactinib and VS-4718, that the development
of the Company’s compounds will take longer or cost more than planned,
and that the Company’s compounds will not receive regulatory approval or
become commercially successful products. Other risks and uncertainties
include those identified under the heading “Risk Factors” in the
Company’s Annual Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com